Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891830434> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2891830434 abstract "e23169 Background: Personalized therapy through the identification of targetable mutations within individual tumors has increasingly become a focus in the management of patients (pts) with relapsed/refractory malignancy. To better understand how this is clinically applied, we reviewed 29 cases of B- and T-cell lymphomas that had genetic sequencing of their tumor. Methods: The electronic medical records of 29 pts who underwent Michigan Oncology Sequencing (MI-ONCOSEQ) testing at the University of Michigan from 2013-2016 were reviewed for disease and treatment history. Reports from whole-genome tumor sequencing were obtained for each patient to identify putative molecular targets. Results: Sixteen male and 13 female pts had a median age of 59 years (range 30-80 years) and median disease stage of IV at diagnosis. Five had CTCL, 5 PTCL, 11 follicular, 1 CLL/ mantle cell (MC), 1 MC, 1 marginal zone, 1 Waldenstrom’s (WM) and 4 DLBCL. Pts received a median of 2 therapies prior to MI-ONCOSEQ biopsy. Targetable mutations were identified in 15 pts and a total of 5 pts underwent MI-ONCOSEQ-based treatments. Bosutinib was given for FYB-FGR fusion, imatinib for FLI1-PDGFRB fusion, and everolimus for activating mTOR mutation with an avg. treatment duration of 3.6 weeks due to progressive disease. Bosutinib and imatinib were 3 rd line therapies and everolimus was 5 th . Another 2 pts were treated with ibrutinib for transformed WM with MYD88 mutation and bortezomib after classification of DLBCL as ABC-type based on MI-ONCOSEQ results, with CR in both. Other targetable mutations identified include BRAF, CDK, BCL2, EZH2 and NOTCH. Of the remaining 12 pts with targetable mutations, 8 pursued clinical trials, 2 responded to standard therapy, 1 died shortly after genetic analysis and 1 declined further therapy. About 50% of these pts remain alive. Conclusions: Our results demonstrate that targeted therapy is favored after standard therapy or clinical trial options are exhausted. Barriers to its use include the availability of clinical trials, off-label drug access and our incomplete knowledge of driver mutations. With further understanding of disease pathogenesis, we expect personalized therapy will be possible for all patients." @default.
- W2891830434 created "2018-09-27" @default.
- W2891830434 creator A5020537159 @default.
- W2891830434 creator A5047177351 @default.
- W2891830434 creator A5062534813 @default.
- W2891830434 creator A5080068122 @default.
- W2891830434 date "2017-05-20" @default.
- W2891830434 modified "2023-09-23" @default.
- W2891830434 title "Clinical applications of genetic sequencing in lymphoma: A retrospective review." @default.
- W2891830434 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23169" @default.
- W2891830434 hasPublicationYear "2017" @default.
- W2891830434 type Work @default.
- W2891830434 sameAs 2891830434 @default.
- W2891830434 citedByCount "0" @default.
- W2891830434 crossrefType "journal-article" @default.
- W2891830434 hasAuthorship W2891830434A5020537159 @default.
- W2891830434 hasAuthorship W2891830434A5047177351 @default.
- W2891830434 hasAuthorship W2891830434A5062534813 @default.
- W2891830434 hasAuthorship W2891830434A5080068122 @default.
- W2891830434 hasConcept C126322002 @default.
- W2891830434 hasConcept C143998085 @default.
- W2891830434 hasConcept C167135981 @default.
- W2891830434 hasConcept C2779338263 @default.
- W2891830434 hasConcept C51679486 @default.
- W2891830434 hasConcept C54355233 @default.
- W2891830434 hasConcept C552990157 @default.
- W2891830434 hasConcept C71924100 @default.
- W2891830434 hasConcept C86803240 @default.
- W2891830434 hasConceptScore W2891830434C126322002 @default.
- W2891830434 hasConceptScore W2891830434C143998085 @default.
- W2891830434 hasConceptScore W2891830434C167135981 @default.
- W2891830434 hasConceptScore W2891830434C2779338263 @default.
- W2891830434 hasConceptScore W2891830434C51679486 @default.
- W2891830434 hasConceptScore W2891830434C54355233 @default.
- W2891830434 hasConceptScore W2891830434C552990157 @default.
- W2891830434 hasConceptScore W2891830434C71924100 @default.
- W2891830434 hasConceptScore W2891830434C86803240 @default.
- W2891830434 hasLocation W28918304341 @default.
- W2891830434 hasOpenAccess W2891830434 @default.
- W2891830434 hasPrimaryLocation W28918304341 @default.
- W2891830434 hasRelatedWork W1506621876 @default.
- W2891830434 hasRelatedWork W2102231609 @default.
- W2891830434 hasRelatedWork W2143067105 @default.
- W2891830434 hasRelatedWork W2203618271 @default.
- W2891830434 hasRelatedWork W2258001933 @default.
- W2891830434 hasRelatedWork W2336636428 @default.
- W2891830434 hasRelatedWork W2396794399 @default.
- W2891830434 hasRelatedWork W2590619183 @default.
- W2891830434 hasRelatedWork W2620392917 @default.
- W2891830434 hasRelatedWork W2624016134 @default.
- W2891830434 hasRelatedWork W2758816105 @default.
- W2891830434 hasRelatedWork W2797357144 @default.
- W2891830434 hasRelatedWork W280734551 @default.
- W2891830434 hasRelatedWork W2916842397 @default.
- W2891830434 hasRelatedWork W2946890991 @default.
- W2891830434 hasRelatedWork W2990876983 @default.
- W2891830434 hasRelatedWork W3082732368 @default.
- W2891830434 hasRelatedWork W3139459873 @default.
- W2891830434 hasRelatedWork W3172218720 @default.
- W2891830434 hasRelatedWork W2890246455 @default.
- W2891830434 isParatext "false" @default.
- W2891830434 isRetracted "false" @default.
- W2891830434 magId "2891830434" @default.
- W2891830434 workType "article" @default.